Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Sylvest was appointed to the commercial strategy and corporate ... across a few other executives. FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks Ludovic ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Novo Nordisk, the Danish maker of Ozempic and Wegovy ... Novo currently sells a diabetes management pill, Rybelsus, which was approved by the FDA in 2019. In 2023, Novo announced promising ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial of Rybelsus found that it significantly reduced the ...

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD ... negotiation for their key drug semaglutide, Wegovy/Ozempic/Rybelsus, in 2027 - it’s not clear how far the Trump ...